3Peason TA,Mensah GA,Alexander RW,et al.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association.Circulation,2003,107(3):499-511.
4Albert MA,Dnielson E,Rifain N,et al.Effect of statin therapy on Creactive protein levels:the pravastst in inflammation/CRPE valvation(PQRlNCE):a randomized trial and cohort study.JAMA,2001,286(1):64.
3Davies M.The pathophysiology of acute coronary syndromes.Heart,2000,83(3):361-366.
4Blankenberg S,Tiret L,Bickel C,et al.Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina.Circulation,2006,106(1):24-30.
5Haverkate F,Thompson SG,Pyke S,et a1.Production of C-reactive protein and risk of coronary events in stable angina and unstable angina:European concerted action on thrombosis and disabilities angina pectoris study group.Lancet,1997,349(4):462-473.
6Scuffham PA,Chaplin S.An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.Pharmacoeconomics,2004,22(8):525-535.
7US Departmentof Healthand Human Services Monograph，1996年，30页
